Lifecore Biomedical, Inc. · Lifecore Inc.
Lifecore Inc. to buy Lifecore Biomedical, Inc. for $238M

Lifecore draws no rival bid as Bambusa and Aspen price IPOs. 1 acquisition, 3 funding rounds, 3 PDUFA dates, 3 officer changes.
Lifecore Biomedical’s September take-private drew no rival bid by the time its go-shop closed on October 28, after outreach to 110 parties.[1] The $6.28 cash price per common share represents a 49.5% premium to the last pre-signing close and implies about $238 million for common stock alone; nearly a quarter of the $663.7 million maximum enterprise value depends on revenue and EBITDA targets.[2][7][1] The target, led by CEO Paul Josephs, is an operating manufacturer that fills and finishes sterile injectables and makes injectable-grade hyaluronic acid.[2] Lifecore Inc. was formed for the deal, but its private equity backer bought half of another contract drug manufacturer in 2022.[1][8]
Both IPOs started with the same proposed terms, 9.375 million shares at $15 to $17, and came out at different prices and sizes.[3][5][4][6] Bambusa Therapeutics added shares and priced at $16 for $168.9 million gross, with plans to take BBT001, its Phase 1 bispecific antibody for atopic dermatitis, into Phase 2b.[3][4] Aspen Neuroscience kept its share count and priced at $15 for $140.6 million gross, with about $110 million earmarked for a Phase 3 trial of sasineprocel, its Phase 1/2a cell therapy for Parkinson’s disease.[5][6]
Private capital backed another early antibody program, but BigHat Biosciences’ October 26 Form D recorded $75.1 million sold in a Series C already announced in September.[9][10] The co-led round backs its AI drug design platform and BHB810, a Phase 1 antibody-drug conjugate for gastric and other advanced gastrointestinal cancers.[10]
The FDA calendar was quieter than it looked: the agency approved bepirovirsen for certain adults with chronic hepatitis B on October 20, before the October 26 “PDUFA action date” Ionis had disclosed.[11][12] Inovio’s October 30 target held, with accelerated approval for Voceryq (INO-3107) “to reduce the frequency of surgery” in adults with recurrent respiratory papillomatosis.[13][14][15] Agios said its response to FDA on whether mitapivat for sickle cell disease needs a REMS “constituted a major amendment,” moving its November 1 goal date to February 1, 2027.[16]
Harmony’s amended 8-K set terms for an already announced succession: COO Peter Anastasiou will succeed retiring president and CEO Jeffrey Dayno in both roles and on the board January 1, with Dayno staying on as an adviser.[17] Spero Therapeutics likewise expects its retiring COO, Timothy Keutzer, to consult after December 31.[18] Bausch + Lomb reported an immediate departure: Nathalie Bernier resigned from the board and its Science and Technology Committee on October 28, and the board had no current plan to fill the seat.[19]
Lifecore Inc. to buy Lifecore Biomedical, Inc. for $238M
IPO of $169M
IPO of $141M
Undisclosed of $75.1M
FDA goal date for mitapivat (sNDA), for sickle cell disease
FDA goal date for INO-3107 (BLA), for recurrent respiratory papillomatosis
FDA goal date for bepirovirsen
Change in directors or officers
Change in directors or officers
Change in directors or officers